MIV-802 / Trek Therapeutics, Medivir - LARVOL DELTA

Medivir licenses rights to MIV-802 to Trek Therapeutics (Medivir Press Release) - "Medivir...and Trek Therapeutics (TREKtx) today announced that TREKtx has licensed the exclusive rights to develop and commercialize MIV-802 globally, excluding China, Taiwan, Hong Kong and Macau...for the treatment of hepatitis C virus (HCV) infection...Medivir is entitled to receive milestones based on successful clinical development and royalties capped at a mid-teens percentage upon commercialization of MIV-802 containing products."

Licensing / partnership • Hepatitis C Virus